Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin Adherence and Hydration Monitoring in Rosacea
NCT04275999Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ivermectin in rosacea (3 arms), sponsored by Wake Forest University Health Sciences. Primary endpoints: Adherence measured by MEMs Cap at Month 3, Adherence measured by Drug Weight and 1 more. Started Apr 2021; status: completed.
02
Drugs
ivermectin
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT04275999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275999.